• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "ipilimumab" 1 results
        • Ipilimumab在惡性黑色素瘤免疫治療中的進展

          ipilimumab是溶解性T細胞相關抗原(CTLA-4)的單克隆抗體。其作用機制為中和CTLA-4的免疫抑制作用,從而激發機體的抗腫瘤免疫反應。在多中心的Ⅲ期臨床試驗中,ipilimumab在延長患者生命方面取得了新的進展,因而美國食品藥品管理局(FDA)批準ipilimumab用于治療晚期惡性黑色素瘤患者,是惡性黑色素瘤免疫治療的重要進步。

          Release date:2016-09-08 09:13 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜